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Abstract
Background: Comorbidity at the time of diagnosis is an independent prognostic factor for survival among women
suffering from cervical or breast cancer. Although cancer screening practices have proven their efficacy for mortality
reduction, little is known about adherence to screening recommendations for women suffering from chronic
conditions. We investigated the association between eleven chronic conditions and adherence to cervical and
breast cancer screening recommendations in France.
Method: Using data from a cross-sectional national health survey conducted in 2008, we analyzed screening
participation taking into account self-reported: inflammatory systemic disease, cancer, cardiovascular disease,
chronic respiratory disease, depression, diabetes, dyslipidemia, hypertension, obesity, osteoarthritis and thyroid
disorders. We first computed age-standardized screening rates among women who reported each condition. We
then estimated the effect of having reported each condition on adherence to screening recommendations in
logistic regression models, with adjustment for sociodemographic characteristics, socioeconomic position, health
behaviours, healthcare access and healthcare use. Finally, we investigated the association between chronic
conditions and opportunistic versus organized breast cancer screening using multinomial logistic regression.
Results: The analyses were conducted among 4226 women for cervical cancer screening and 2056 women for
breast cancer screening. Most conditions studied were not associated with screening participation. Adherence
to cervical cancer screening recommendations was higher for cancer survivors (OR = 1.73 [0.98–3.05]) and lower
for obese women (OR = 0.73 [0.57–0.93]), when accounting for our complete range of screening determinants.
Women reporting chronic respiratory disease or diabetes participated less in cervical cancer screening, except
when adjusting for socioeconomic characteristics. Adherence to breast cancer screening recommendations was
lower for obese women and women reporting diabetes, even after accounting for our complete range of screening
determinants (OR = 0.71 [0.52–0.96] and OR = 0.55 [0.36–0.83] respectively). The lower breast cancer screening
participation for obese women was more pronounced for opportunistic than for organized screening.
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Conclusion: We identified conditions associated with participation in cervical and breast cancer screening, even
when accounting for major determinants of cancer screening. Obese women participated less in cervical cancer
screening. Obese women and women with diabetes participated less in mammographic screening and organized
breast cancer screening seemed to insufficiently address barriers to participation.
Keywords: Cancer screening, Breast neoplasms, Uterine cervical neoplasms, Chronic disease, Comorbidity, France
Background
Chronic disease morbidity is an issue of increasing im-
portance for cancer research [1]. While chronic condi-
tions are already the leading cause of death globally and
their burden is expected to increase [2], it has now been
shown that all-cause mortality as well as cancer-specific
mortality is higher for newly diagnosed cancer patients
suffering from chronic conditions, even when stage at
diagnosis or treatment are taken into account [3, 4].
More specifically, comorbidity at the time of diagnosis is
an independent prognostic factor for survival among
both cervical cancer [5, 6] and breast cancer patients [7,
8]. A recent study showed that the presence of one
chronic condition was equivalent to one tumor stage
shift in terms of breast cancer survival decrease [9].
Among available tools for cancer control, cervical
smears have proved their efficacy to reduce cervical can-
cer incidence and mortality [10, 11]. For breast cancer,
although the portion of mortality reduction attributable
to screening has been subject to controversy [12, 13], re-
cent studies have found a 10 to 20 % reduction in breast
cancer mortality among women who underwent mam-
mographic screening [14–16]. In France, cervical cancer
screening is recommended every three years for women
aged 25 to 65 years and is based on individual cervical
smear use (opportunistic screening). A nationwide orga-
nized breast cancer screening has been implemented in
2004 and women aged 50 to 74 years are individually in-
vited to attend mammography screening, free of charge,
every two years. This organized program exists alongside
opportunistic screening, since individual prescriptions of
mammograms are reimbursed.
Yet, inconsistent results have been reported regarding
adherence to recommended screening procedures among
patients suffering from chronic diseases [17]. Some condi-
tions are generally associated with higher cancer screening
rates (e.g. cancer survivors [18]), others with lower cancer
screening rates (e.g. diabetes [19]) and contradictory re-
sults are reported for conditions such as rheumatoid arth-
ritis [20, 21]. When the overall effect of chronic morbidity
on cervical and breast cancer screening is studied using
summary measures, increased comorbidity is associated
with decreased screening in clinic-based studies [21] and
with increased screening in population-based studies [22].
In addition, these studies did not systematically investigate
the factors explaining the association between the pres-
ence of chronic diseases and cancer screening participa-
tion. Evidence on screening determinants is now extensive
[23] and a large range of variables are associated with
smear use or mammography, including demographic and
socioeconomic characteristics, health behaviours and
healthcare related variables [24, 25]. There is also evidence
that fewer factors are associated with screening participa-
tion when organized programs exist. In particular, women
with lower socioeconomic positions are more likely to at-
tend screening through organized programs than through
opportunistic screening [26–28].
In this context, our primary objective was to identify
chronic conditions associated with adherence to cervical
and breast cancer screening recommendations in France
and to investigate whether these associations were modi-
fied by several major cancer screening determinants.
Our secondary objective was to explore whether the as-
sociations between chronic conditions and breast cancer




Our study was based on data from the 2008 wave of the
Healthcare and Health Insurance Survey (Enquête Santé
et Protection Sociale), a national health survey conducted
by the Institute for Research and Information on Health
Economics. Information was collected among a random
sample of non-institutionalized health-insured people
living in mainland France and from all the members of
their households. The overall sample included 22,273 in-
dividuals spread over 8,257 households. All individuals
were interviewed to collect information on sociodemo-
graphic characteristics and received a questionnaire for
health-related questions and screening behavior. Overall
response rate to this self-reported health questionnaire
was 72 % [29].
Outcome
The two outcomes were adherence to the French Health
authority’s cervical and breast cancer screening recom-
mendations: having undergone a cervical smear within
the last three years for women aged 25 to 65 years and
having undergone a mammography within the last two
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years for women aged 50 to 74 years. The reason for
undergoing mammography was available, which allowed
us to distinguish opportunistic from organized screening
participation. Official exclusion criteria were applied.
Women who reported both cancer diagnosis and last
screening use within the recommended interval were
not excluded, as cancer could have been diagnosed dur-
ing the last screening, and thus does not constitute an
exclusion criterion. The selection process for the studied
samples is presented in Fig. 1.
Chronic conditions
Morbidity at the time of the survey was self-reported
from among an extensive checklist of more than 50
conditions, with the possibility of free text declara-
tions. For each reported condition, the respondents
indicated if they had been treated within the last
12 months. For each respondent, the list of reported
chronic conditions was retrospectively validated by a
physician, as part of the Healthcare and Health
Insurance Survey study, using answers to questions
including past 24 hours’ medication consumption, his-
tory of surgery or prosthetics, reason for last medical
appointment or long-term illness fee exemption (cor-
responding to the full reimbursement of medical fees
for a specific condition). For the purpose of this ana-
lysis, we reviewed all the conditions reported to define
the eleven most common and mutually exclusive
chronic conditions: inflammatory systemic disease
(arthritis or vascularitis or inflammatory bowel dis-
ease), cancer (other than: cervical cancer, for cervical
cancer screening sample and breast cancer, for breast
cancer screening sample), cardiovascular diseases,
chronic respiratory diseases, depression, diabetes, dys-
lipidemia, hypertension, obesity, osteoarthritis and
thyroid disorders. For depression, dyslipidemia and
hypertension, we restricted the selection to women who
reported having been treated within the last 12 months,
due to the poor specificity of these self-reported condi-
tions. Obesity was defined using body mass index (BMI),
calculated using self-reported weight and height (obesity if
BMI > =30 kg/m2).
women aged 25-65 
included in overall sample














women reporting both smear use 
and cervical cancer diagnosis 
within the last three years
n = 1  
women eligible for 
cervical cancer screening
n = 4320
Eligible women with 
missing values for smear use
n = 94
Final sample for 
cervical cancer screening 
eligible women
n = 4226
women aged 50-74 
included in overall sample














women reporting both mammography use 
and breast cancer diagnosis 
within the last two years
n = 17  
women eligible for 
breast cancer screening
n = 2113
Eligible women with 
missing values for mammography use
n = 57
Final sample of 
breast cancer screening 
eligible women
n = 2056
Fig. 1 Flowcharts describing the cervical (left panel) and breast cancer (right panel) screening sample selection
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Covariates
To investigate whether the association between chronic
conditions and screening participation was modified by
the major screening determinants, we classified adjust-
ment variables into five acknowledged categories of
determinants [23, 25]. We selected the variables signifi-
cantly associated in univariate analysis with screening
participation and with the majority of studied condi-
tions. We then assessed pairwise correlation between
variables within each category of determinants and mul-
ticollinearity among all variables to define the final list
of covariates. The following groups were defined: socio-
demographic characteristics: age (categorized for breast
cancer in 5-year groups and for cervical cancer as fol-
lows: 25–39, 40–49 and then 5-year groups), household
composition (single adult without children/couple with-
out children/single adult with children/couple with chil-
dren); socioeconomic position: highest educational level
attained (primary education or less/did not graduate
high school/graduated high school/higher than high
school), housing tenure (renter/owner with mortgage/
outright owner), employment status (inactive/employed/
unemployed/retired); health behaviours: smoking (never
smokers/current smokers/ex-smokers); healthcare access:
complementary health insurance status (none/private/free
coverage for low income individuals), long-term illness fee
exemption (yes/no); healthcare use: physicians consulted
within the last 12 months (at least one gynecologist/other
physician(s)/none)
Statistical analyses
All analyses were conducted for cervical and breast can-
cer screening separately. We first computed age-
standardized screening rates among the subgroups of
women suffering from each chronic condition of inter-
est, with direct standardization, using the age distribu-
tion of the entire eligible population as standard.
We then compared screening participation between
women with each chronic condition of interest versus
women without the condition, using logistic regression
modeling. For all models, adherence to screening recom-
mendations was the dependent variable and chronic
conditions were specified as dichotomous explanatory
variables. All models were systematically adjusted for
age. Models were also adjusted for our five categories of
determinants: sociodemographic characteristics, socio-
economic position, health behaviours, healthcare access
and healthcare use, first separately and then simultan-
eously in a fully-adjusted model.
Additional analyses were conducted to disentangle the
effect of the chronic condition of interest from that of
other concomitant conditions: (i) for each condition, we
additionally adjusted our fully-adjusted model for the
number of conditions reported; (ii) we studied the
association between screening participation and each
condition when coded as a categorical variable (condi-
tion reported alone or with 1, 2 or 3 or more other con-
ditions among the 11 conditions studied).
Finally, the association between breast cancer screening
and the presence of chronic conditions was investigated
by type of screening (organized versus opportunistic)
using multinomial logistic regression.
For the covariates, missing values were rare (<4 %) ex-
cept for smoking (10.9 % in the cervical cancer screening
sample and 19.0 % in the breast cancer screening
sample) and were treated as a separate category in
the analyses. For the chronic condition variables,
there were no missing values except for obesity (4 %).
These women were considered as a separate category.
Sensitivity analyses showed similar results when clas-
sifying missing values as obese or non-obese. Avail-
able sampling weights to account for the survey’s
sampling design and overall non-response were ap-
plied and our estimates can be extrapolated to the
entire non-institutionalized French mainland popula-
tion living in households.
All statistical analyses were performed using Stata 11
software in survey mode (StataCorp. 2009. Stata Statis-
tical Software: Release 11. College Station, TX: StataCorp
LP).
Ethics
The Healthcare and Health Insurance Survey waves con-
ducted biennially by the Institute for Research and Infor-
mation on Health Economics (IRDES) are approved by
the national administrative authority on data protection
(CNIL, Commission Nationale de l’Informatique et des
Libertés, authorization n°1147702-V2). Databases are
available upon request and research collaboration with
the IRDES. Written informed consent was not required
for this study as all data were anonymized.
Results
Study population
The cervical cancer screening sample included 4,226
women aged 25–65 years and the breast cancer screen-
ing sample included 2,056 women aged 50–74 years
(Fig. 1). Prevalence of the studied conditions among cer-
vical and breast cancer screening eligible women are
presented in Tables 1 and 2, respectively. The most
prevalent reported conditions were osteoarthritis (re-
ported by 16.0 % of women in the cervical cancer
screening sample and 35.8 % of women in the breast
cancer screening sample), obesity (12.1 % and 15.3 % re-
spectively) and hypertension (8.1 % and 18.8 % respect-
ively). The distribution of covariates among eligible
women is available in Additional file 1: Table S1.
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Cervical cancer screening (Tables 1 and 3)
The overall cervical cancer screening rate was 75.8 %
[95 % confidence interval 74,5-77,2]. When compared
with the whole population, age-standardized screening
rates were lower among women reporting chronic re-
spiratory diseases (67.7 % [62.3–73.2]) and among obese
women (65.0 % [60.7–69.3]). Although not statistically
significant, the lowest screening rate was observed
among women reporting diabetes (63.6 % [51.3–76.0])
(Table 1). For each chronic condition of interest, we
present in Table 3 the odds ratios (OR) of screening par-
ticipation for women having versus not having reported
this condition. Women with a history of cancer were more
likely to adhere to screening recommendations. The asso-
ciation was nevertheless markedly reduced when account-
ing for healthcare use (OR = 1.38 [0.82–2.32]). Lower
Table 1 Prevalence of and cervical cancer screening rate for the studied conditions
Sample size Age
N %a (mean,σ) N rateb [95 % CI]
All women 4226 100 44,6 (11,0) 3201 75,8 [74,5-77,2]
Inflammatory systemic diseasec 98 2,4 48,9 (10,8) 66 72,5 [63,8-81,2]
Cancerd 122 3,0 52,3 (9,2) 98 80,1 [69,3-91,0]
Cardiovascular disease 87 2,1 51,7 (9,5) 59 74,0 [64,7-83,2]
Chronic Respiratory disease 294 7,2 45,4 (11,4) 199 67,7 [62,3-73,2]
Depressione 177 4,7 46,7 (10,3) 137 76,3 [69,3-83,4]
Diabetes 122 2,9 54,1 (8,0) 67 63,6 [51,3-76,0]
Dyslipidemiae 167 4,1 55,0 (7,4) 117 74,7 [63,9-85,5]
Hypertensione 331 8,1 53,7 (8,1) 228 74,5 [68,1-80,9]
Obesity 518 12,1 46,5 (11,2) 326 65,0 [60,7-69,3]
Osteoarthritis 653 16,0 52,4 (8,8) 465 74,1 [69,8-78,3]
Thyroid disorders 323 7,6 48,3 (9,8) 248 77,6 [72,7-82,4]
aweighted percentages (to account for the survey’s sampling design and overall non-response)
bage-standardized weighted rates (the age distribution of “all women” was used as standard for each screening)
carthritis or vascularitis or inflammatory bowel disease
dother than cervical cancer
etreated within the last 12 months
Table 2 Prevalence of and breast cancer screening rate for the studied conditions
Sample size Age Overall screening Organized screening Opportunistic screening
N %a (mean,σ) N rateb [95 % CI] N rateb [95 % CI] N rateb [95 % CI]
All women 2056 100 60,2 (7,0) 1533 74,9 [73.0-76.9] 1091 54,4 [52,2-56,6] 374 17,2 [15.6-18.8]
Inflammatory systemic diseasec 84 4,3 62,7 (7,2) 67 79,3 [70,2-88,4] 50 58,3 [47,0-69,5] 13 16,6 [1, 1-8, 8-25]
Cancerd 67 3,4 63,1 (7,0) 48 76,0 [65,8-86,2] 33 51,4 [38,5-64,3] 11 20,1 [9,1-31,0]
Cardiovascular disease 96 4,9 64,0 (7,4) 69 69,7 [59,8-79,7] 57 56,4 [46,7-66,1] 9 10,9 [3,1-18,7]
Chronic Respiratory disease 173 8,8 61,5 (7,0) 124 69,0 [61,7-76,2] 106 57,8 [50,2-65,4] 14 9,3 [4,3-14,2]
Depressione 85 4,7 59,1 (6,6) 58 66,1 [55,3-77,0] 36 46,5 [35,4-57,5] 17 14,6 [8,3-21,0]
Diabetes 157 7,6 62,7 (7,4) 91 59,7 [51,4-67,9] 64 42,1 [33,8-50,4] 20 14,1 [8,1-20,0]
Dyslipidemiae 234 11,8 63,2 (6,9) 179 77,9 [72,0-83,8] 143 62,7 [55,9-69,5] 33 14,1 [9,2-18,9]
Hypertensione 369 18,8 62,0 (7,1) 279 76,2 [71,7-80,9] 216 59,2 [54,0-64,5] 55 15,2 [11,4-19,0]
Obesity 319 15,3 61,0 (6,9) 212 67,2 [61,8-72,6] 167 53,9 [48,3-59,6] 38 11,3 [7,8-14,8]
Osteoarthritis 707 35,8 62,4 (7,1) 539 75,9 [72,4-79,3] 410 57,3 [53,4-61,1] 108 15,8 [12,9-18,7]
Thyroid disorders 253 12,5 62,0 (7,2) 194 76,0 [70,4-81,7] 140 53,6 [47,2-60,1] 45 19,3 [14,1-24,4]
aweighted percentages (to account for the survey’s sampling design and overall non-response)
bage-standardized weighted rates (age distribution of “all women” was used as standard for each screening)
carthritis or vascularitis or inflammatory bowel disease
dother than breast cancer
etreated within the last 12 months
Note: some respondents reported mammography use within the last two years without precision on screening mode. Therefore, the number of women who
participated in organized and opportunistic breast cancer screening may not always add up to the overall number of women who participated in breast
cancer screening
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adherence to screening recommendations was found for
women reporting chronic respiratory diseases, diabetes or
obesity. Socioeconomic factors accounted for this lower
participation for chronic respiratory diseases (OR = 0.79
[0.60–1.05]) and diabetes (OR = 0.72 [0.48–1.09]). For
obese women however, statistically significant lower
screening participation was still observed in the fully ad-
justed model (OR = 0.73 [0.57–0.93]). Our results were ro-
bust to further adjustment for the number of conditions
reported among the 11 studied (results not shown). The
association was even strengthened for women reporting
obesity or cancer without any additional comorbidity (OR
= 0.56 [0.39–0.79] and OR = 3.17 [1.24–8.10] respectively,
in the fully-adjusted model).
Breast cancer screening (Tables 2, 4 and 5)
The overall breast cancer screening rate was 74.9 %
[73.0–76.9]. When compared with the whole population,
age-standardized screening rates were lower among
women reporting diabetes (59.7 % [51.4–67.6]) and
among obese women (67.2 % [61.8–72.6]) (Table 2).
Significantly lower adherence to screening recommenda-
tions was observed for women reporting diabetes or
obese women in all models (OR = 0.55 [0.36–0.83] for
diabetes, OR = 0.71 [0.52–0.96] for obesity, in the fully-
adjusted model). Our results were robust to further ad-
justment for the number of conditions reported among
the 11 studied (results not shown). Associations were
strengthened for women reporting diabetes or obesity
without any additional comorbidity (OR = 0.33 [0.13–
0.82] and OR = 0.41 [0.21–0.78] respectively in the fully-
adjusted model). As diabetes and obesity are frequently
associated, we further investigated the association be-
tween breast cancer screening participation and com-
bined or independent exposure to diabetes and obesity.
When compared to women reporting neither diabetes
nor obesity, lower screening rates were observed for
women reporting both conditions (OR = 0.41 [0.23–0.73]
in the fully-adjusted model) or diabetes alone (OR = 0.54
[0.31–0.92]) whereas the association was not statistically
significant for women reporting obesity alone (OR = 0.74
[0.53–1.04]).
Table 5 presents the association between participation
in organized and opportunistic breast cancer screening
and chronic conditions. We only present results adjusted
for age, for age and socioeconomic position and for all
screening determinants and for conditions with signifi-
cant estimates. Women reporting chronic respiratory


















adjustedgOR [95 % CI]
OR [95 % CI]
OR [95 % CI] OR [95 % CI]OR [95 % CI] OR [95 % CI]OR [95 % CI]
Inflammatory systemic
diseaseh
0.82 [0.53-1.29] 0,78 [0,49-1,25] 0,82 [0,50-1,35] 0,81 [0,51-1,27] 0,83 [0,52-1,33] 0.88 [0.55-1.42] 0,82 [0,48-1,39]
Canceri 1.53 [0.94-2.51] 1,54 [0,95-2,51] 1,76 [1,04-2,98] 1,63 [1,00-2,68] 2,00 [1,20-3,34] 1.38 [0.82-2.32] 1,73 [0,98-3,05]
Cardiovascular diseases 0.77 [0.47-1.25] 0,81 [0,50-1,34] 0,93 [0,57-1,52] 0,81 [0,49-1,34] 0,91 [0,54-1,51] 0.84 [0.50-1.41] 1,07 [0,61-1,86]
Chronic respiratory
diseases
0.65 [0.49-0.85] 0,71 [0,54-0,93] 0,79 [0,60-1,05] 0,67 [0,51-0,87] 0,72 [0,54-0,96] 0.64 [0.48-0.85] 0,82 [0,60-1,13]
Depressionj 1.11 [0.75-1.65] 0,27 [0,85-1,89] 1,35 [0,90-2,03] 1,16 [0,79-1,72] 1,27 [0,84-1,91] 1.05 [0.68-1.62] 1,33 [0,84-2,09]
Diabetes 0.49 [0.33-0.72] 0,53 [0,35-0,78] 0,72 [0,48-1,09] 0,50 [0,34-0,74] 0,56 [0,36-0,85] 0.53 [0.34-0.83] 0,71 [0,44-1,15]
Dyslipidemiaj 0.98 [0.68-1.43] 1,01 [0,70-1,47] 1,08 [0,74-1,57] 0,95 [0,66-1,39] 1,04 [0,71-1,51] 0.73 [0.49-1.11] 0,79 [0,53-1,19]
Hypertensionj 0.89 [0.68-1.16] 0,91 [0,69-1,20] 0,95 [0,72-1,26] 0,87 [0,66-1,14] 0,92 [0,70-1,21] 0.86 [0.64-1.15] 0,92 [0,68-1,25]
Obesity 0.52 [0.43-0.65] 0,56 [0,45-0,69] 0,66 [0,53-0,83] 0,52 [0,42-0,65] 0,58 [0,46-0,72] 0.61 [0.48-0.76] 0,73 [0,57-0,93]
Osteoarthritis 0.91 [0.74-1.12] 0,95 [0,77-1,17] 1,06 [0,86-1,32] 0,90 [0,73-1,10] 0,97 [0,78-1,19] 0.85 [0.68-1.06] 0,96 [0,76-1,21]
Thyroid disorders 1.12 [0.85-1.49] 1,12 [0,85-1,48] 1,14 [0,85-1,53] 1,11 [0,84-1,48] 1,12 [0,84-1,48] 1.03 [0.76-1.39] 1,04 [0,76-1,42]
OR odds ratio
95 % CI: 95 % confidence interval
athe reference category is women who have not reported the condition of interest
badjusted for age and household composition
cadjusted for age and highest educational level attained, housing tenure, employment status
dadjusted for age and smoking
eadjusted for age and complementary health insurance status, long-term illness fee exemption
fadjusted for age and physician consulted within the last 12 months
gadjusted for all covariates
harthritis or vascularitis or inflammatory bowel disease
iother than cervical cancer
jtreated within the last 12 months
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diseases participated less in opportunistic screening only.
Lower screening rates were found for both types of
screening among women reporting diabetes and among
obese women. This lower participation was nevertheless
more pronounced for opportunistic screening for obese
women (OR = 0.54 [0.34–0.86] vs OR = 0.78 [0.57–1.08]
in the fully-adjusted model).
Discussion
Adherence to cervical cancer screening recommendations
was higher for cancer survivors and lower for obese women
when compared to women who did not report these condi-
tions. Lower participation in cervical cancer screening was
also observed for women reporting chronic respiratory dis-
eases or diabetes, except when adjusting for socioeconomic
characteristics. Adherence to breast cancer screening rec-
ommendations was lower for obese women and women
reporting diabetes, even after accounting for our complete
range of screening determinants. The lower breast cancer
screening participation for obese women was more pro-
nounced for opportunistic than for organized screening.
Findings in relation to other studies and interpretation
Only few studies investigated the association between a
large range of chronic conditions and cancer screening
as we did and they also suggested that most conditions
were not associated with screening participation [21, 22].
Contrasted findings were nevertheless observed for
rheumatoid arthritis [20, 21] and respiratory diseases,
with differences between asthma and COPD [21]. Con-
sistent with our findings, most studies [18], although not
all [22], reported that adherence to recommended can-
cer screening practices was higher among cancer survi-
vors. Lower cervical and breast cancer screening use has
also been repeatedly reported among women with dia-
betes, both in clinic-based and population-based studies
[19, 21, 30], as well as among obese women [31, 32].
However, the available literature reported that hyperten-
sion was associated with an increased cervical cancer
screening [21, 22], an association that we did not find.
Cancer is among the rare chronic conditions associated
with higher cervical smear or mammography use. How-
ever, it is unclear whether this association remains when
breast (for cervical smear) or cervical (for mammography)
cancer survivors are excluded [18]. We observed that
higher cervical cancer screening participation was re-
stricted to breast cancer survivors (results not shown) and
was largely accounted for by healthcare use. We therefore
hypothesize that a history of breast cancer is likely to in-
duce a more frequent gynecological follow-up that in turn


















adjustedgOR [95 % CI]
OR [95 % CI]
OR [95 % CI] OR [95 % CI]OR [95 % CI] OR [95 % CI]OR [95 % CI]
Inflammatory systemic
diseaseh
1.29 [0.73-2.28] 1,27 [0,72-2,24] 1,28 [0,73-2,27] 1,24 [0,70-2,19] 1,48 [0,83-2,65] 1.46 [0.79-2.68] 1,51 [0,82-2,78]
Canceri 0.91 [0.51-1.60] 0,94 [0,53-1,66] 0,97 [0,54-1,74] 0,92 [0,52-1,63] 1,17 [0,64-2,16] 0.85 [0.48-1.51] 1,10 [0,58-2,06]
Cardiovascular diseases 0.93 [0.57-1.51] 0,93 [0,57-1,52] 1,08 [0,65-1,78] 0,97 [0,60-1,58] 1,19 [0,72-1,97] 0.90 [0.55-1.47] 1,22 [0,72-2,05]
Chronic respiratory diseases 0.79 [0.54-1.14] 0,81 [0,56-1,17] 0,94 [0,65-1,36] 0,81 [0,56-1,17] 0,91 [0,62-1,32] 0.79 [0.54-1.15] 0,96 [0,64-1,42]
Depressionj 0.73 [0.44-1.20] 0,77 [0,46-1,29] 0,88 [0,54-1,44] 0,74 [0,45-1,22] 0,89 [0,53-1,48] 0.67 [0.39-1.15] 0,84 [0,48-1,45]
Diabetes 0.46 [0.32-0.65] 0,48 [0,33-0,68] 0,52 [0,36-0,74] 0,44 [0,31-0,63] 0,53 [0,35-0,79] 0.48 [0.33-0.70] 0,55 [0,36-0,83]
Dyslipidemiaj 1.17 [0.83-1.64] 1,20 [0,86-1,69] 1,25 [0,89-1,77] 1,16 [0,82-1,64] 1,21 [0,86-1,71] 1.05 [0.73-1.49] 1,13 [0,78-1,62]
Hypertensionj 1.06 [0.80-1.39] 1,07 [0,81-1,41] 1,10 [0,83-1,46] 1,02 [0,77-1,36] 1,09 [0,82-1,45] 1.01 [0.76-1.35] 1,03 [0,76-1,39]
Obesity 0.61 [0.46-0.80] 0,62 [0,47-0,81] 0,69 [0,52-0,92] 0,59 [0,45-0,78] 0,65 [0,49-0,86] 0.64 [0.48-0.86] 0,71 [0,52-0,96]
Osteoarthritis 1.13 [0.90-1.42] 1,15 [0,92-1,45] 1,21 [0,96-1,54] 1,12 [0,89-1,41] 1,17 [0,93-1,47] 1.09 [0.86-1.38] 1,16 [0,91-1,48]
Thyroid disorders 1.13 [0.81-1.57] 1,11 [0,80-1,55] 1,04 [0,75-1,45] 1,14 [0,82-1,58] 1,19 [0,85-1,67] 0.99 [0.71-1.40] 1,00 [0,70-1,41]
OR odds ratio
95 % CI: 95 % confidence interval
athe reference category is women who have not reported the condition of interest
badjusted for age and household composition
cadjusted for age and highest educational level attained, housing tenure, employment status
dadjusted for age and smoking
eadjusted for age and complementary health insurance status, long-term illness fee exemption
fadjusted for age and physician consulted within the last 12 months
gadjusted for all covariates
harthritis or vascularitis or inflammatory bowel disease
iother than breast cancer
jtreated within the last 12 months
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largely accounts for the higher cervical cancer screening
participation for breast cancer survivors.
Obesity was significantly associated with lower partici-
pation in cervical and breast cancer screening in our
study, even when accounting for a large range of deter-
minants. Qualitative research underlines that obese
women face both the usual patient-related barriers to
screening, such as fear or embarrassment, and specific
weight-related barriers, such as inadequate equipment or
negative interaction with physicians [33]. We compared
obese to non-obese women. However, consistent with
the literature [34], we found an inverse gradient between
BMI and cervical or breast cancer screening uptake (re-
sults not shown). The lower cancer screening uptake
that we observed for obese women would then have
been more pronounced had we compared obese to nor-
mal weight women.
Both obesity and diabetes are associated with a higher
risk of postmenopausal breast cancer. Numerous studies
have reported a gradient between BMI and postmeno-
pausal breast cancer risk: compared with normal weight
women, cancer risk is significantly higher for overweight
women and continues to rise for obese women [35]. For
diabetes, the association with breast cancer is more
modest and the carcinogenesis mechanism is less clear
than the exposure to elevated circulating estrogen levels
in obese women. However, a recent meta-analysis con-
cluded in a significant association between type II dia-
betes and postmenopausal breast cancer, persistent
when adjusting for BMI [36]. Obese women or women
with diabetes are therefore at the same time less covered
by mammographic prevention and more exposed to
postmenopausal breast cancer risk.
Women suffering from chronic conditions are more
likely to have a regular medical follow-up. This may be
particularly true for conditions with standardized follow-
up procedures such as diabetes. The possible role of
medical follow-up in adherence to cancer screening rec-
ommendations, however, is not clear. It has been sug-
gested that physicians concentrated on specific chronic
disease management at the expense of other preventive
care practices, including cancer screening, both among
diabetic women [37] or obese people [38]. On the other
hand, there is evidence that cancer screening rates in-
crease with increasing number of chronic conditions
[39], suggesting that competing demand is not a suffi-
cient explanation for lower screening participation
among women with diabetes or obesity. In addition, a
more frequent medical follow-up has been associated
with higher cancer screening rates among individuals
with diabetes [19, 37] and with more physician recom-
mendations for cervical smear among obese women
[34]. Finally, although similar findings are observed for
obese and diabetic women, obesity does not require a
medical diagnosis and many obese women are not
treated for obesity until they develop another chronic
condition. In our study, healthcare use did not explain
the lower screening participation for women with dia-
betes or obese women. The relevant factor may not be
the frequency of medical follow-up but the quality of
Table 5 Odds ratiosa of participation in organized and opportunistic breast cancer screening for selected chronic conditions
No screening Organized screening Opportunistic screening Wald testb (p)
OR [95 % CI] OR [95 % CI]
Chronic Respiratory disease
Age-adjusted model 1 0,92 [0,63-1,34] 0,42 [0,22-0,81] 0,01
Age and socioeconomic
position-adjusted modelc
1 1,08 [0,74-1,57] 0,53 [0,27-1,01] 0,02
Fully-adjusted modeld 1 1,11 [0,74-1,66] 0,54 [0,27-1,11] 0,03
Diabetes
Age-adjusted model 1 0,45 [0,30-0,65] 0,47 [0,27-0,81] 0,85
Age and socioeconomic
position-adjusted modelc
1 0,49 [0,34-0,73] 0,60 [0,34-1,05] 0,51
Fully-adjusted modeld 1 0,50 [0,32-0,79] 0,71 [0,37-1,36] 0,25
Obesity
Age-adjusted model 1 0,68 [0,51-0,91] 0,42 [0,27-0,63] 0,01
Age and socioeconomic
position-adjusted modelc
1 0,77 [0,57-1,04] 0,51 [0,33-0,78] 0,04
Fully-adjusted modeld 1 0,78 [0,57-1,08] 0,54 [0,34-0,86] 0,08
aORs refer to women having reported the condition of interest when compared to women who have not reported this condition
btests the significance of the difference between the ORs for organized and opportunistic screening (regardless of the significance of each OR)
cadjusted for age and highest educational level attained, housing tenure, employment status
dadjusted for all covariates
Constantinou et al. BMC Cancer  (2016) 16:255 Page 8 of 11
care. Indeed, there is evidence that among women with
diabetes, the adherence to screening recommendations
is associated to the quality of diabetes-related processes
of care [40]. Our measure of medical follow-up, however,
did not allow us to study the quality of processes of care.
Socioeconomic status accounted for the lower cervical
cancer screening participation for women reporting
chronic respiratory diseases or diabetes in our study.
This effect was expected, as low socioeconomic status is
associated with both lower screening rates [41] and most
of the conditions investigated, in particular diabetes [42].
Studies also report that organized compared to oppor-
tunistic screening led to decreased socioeconomic in-
equalities in screening participation [26, 27]. This is
likely to explain why socioeconomic characteristics had
a larger effect on cervical cancer screening participation,
where no nationwide organized screening program was
available, than on breast cancer screening participation.
Also, although estimates of the screening mode compar-
isons for breast cancer should be considered with cau-
tion because of small sample sizes, we found a similar
pattern between cervical cancer screening and opportun-
istic breast cancer screening, with socioeconomic pos-
ition accounting for the lower participation for women
reporting chronic respiratory disease or diabetes.
Although a recent evaluation suggests that exclusive
organized screening would be more efficient than the ac-
tual coexistence of both screening modes in France [43],
lower organized breast cancer screening participation
was observed for women reporting diabetes. Our find-
ings therefore suggest that other factors than those in-
vestigated in our study still constitute barriers to
screening, which organized screening may not have yet
been able to address.
Strengths and limitations
We used data from a large national survey, taking
advantage of the survey’s overall sample size to study a
substantial number of chronic conditions and explana-
tory variables. Our objective was to analyze the
association between common chronic conditions and
recommended cancer screening use but due to too small
sample sizes, we could not restrict our analyses to
women suffering from one single condition. In order to
investigate the independent effect of each condition we
conducted several additional analyses to test the robust-
ness of our results: we accounted for the number of
chronic conditions reported, as some studies found that
the association between cancer screening participation
and chronic conditions disappeared with this adjustment
[21]; we studied the association with screening participa-
tion when the conditions were reported without add-
itional disease; and we investigated the combined and
independent effect of diabetes and obesity. The stability
of our results across all analyses strongly supports an in-
dependent effect of the identified chronic conditions on
screening participation.
The quality of our data should be discussed. As 25 %
of women aged 25–74 included in the survey did not re-
turn the health questionnaire and therefore did not pro-
vide information on chronic conditions and screening
participation, selection bias is an issue. However, a proxy
for chronic condition ascertainment, the report of a
long-term illness fee exemption, as well as most
screening determinants (except smoking and visits to
physicians within the last year) were available for all
respondents. We assessed the magnitude of the selec-
tion bias by comparing the distribution of these covar-
iates between women who did and did not return the
health questionnaire. The distribution of the proxy for
chronic condition ascertainment did not differ be-
tween these two groups. Regarding the screening de-
terminants, response rate was lower among women
under the age of 40, living in couple with children, in-
active, without complementary health insurance and
higher among women over the age of 60, living alone
without children, retired, with free insurance for low
income. However, women with higher (lower) re-
sponse rate were not systematically those with higher
(lower) screening participation (Additional file 1:
Table S1). We therefore believe that the selection bias
is not likely to account for our results.
Screening participation and morbidity data were self-
reported. Although self-reported cervical and breast can-
cer screening participation is thought to overestimate ac-
tual use, population-based surveys with questionnaires
could be considered the most valid and the accuracy of
self-reporting does not seem to be associated with socio-
economic factors [44]. We lack data however on the ac-
curacy of self-reported screening participation according
to the presence of chronic conditions. Finally, although
chronic disease ascertainment was validated by physi-
cians and in spite of the great attention given to the def-
inition of the studied conditions, data on chronic
diseases may still suffer from bias. First, because of the
cross-sectional design of the survey, the chronic condi-
tion may not always have been present at the time of
screening and prevalence could be overestimated. Sec-
ond, the validity of chronic disease ascertainment with
population-based data depends on the conditions stud-
ied. The strongest agreement with administrative data is
observed for diabetes or hypertension but prevalence of
conditions such as arthritis or heart disease may be
underestimated in self-reported population-based stud-
ies, with a tendency to identify less healthy people [45,
46]. It has also been shown that BMI was underesti-
mated when self-reported, especially among obese or
elderly people [47, 48].
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Overall, we believe that our results, especially for dia-
betes and obesity, are not likely to be explained by self-
reporting bias. Finally, although consistent with the
literature, we cannot rule out that for the majority of the
conditions studied, the lack of association with cervical
and breast cancer screening participation may be ex-
plained by less accurate self-reporting, especially for con-
ditions with intermittent and non-specific symptoms (e.g.
chronic respiratory conditions) or non-life-threatening
conditions (e.g. arthritis) [45, 46].
Conclusion
Cancer screening is only one among the available tools
for cancer control but it has proven its efficacy for cer-
vical and breast cancer mortality reduction. We identi-
fied conditions associated with cervical and breast
cancer screening participation and investigated the de-
terminants explaining these associations. Obese women
participated less in cervical cancer screening use and, al-
though at higher risk of postmenopausal breast cancer,
obese women and women reporting diabetes are less
likely to follow mammographic screening recommenda-
tions. Noteworthy, organized breast cancer screening
seems to insufficiently address barriers to screening
among these exposed populations. Further investigation
is needed to better understand cancer screening deter-
minants among chronically ill women and to design in-
terventions that efficiently increase screening coverage
in these groups.
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